Azenta, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AZTA in the last 30 days.
See all $AZTA insider activity →Azenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.
Azenta (AZTA) granted its interim CEO, Martin D. Madaus, 36,653 restricted stock units (RSUs) on September 14, 2026. The RSUs vest monthly over 12 months and will settle in common stock, increasing Madaus' direct holdings to 44,058 shares. No payment was made for the grant, and no Rule 10b5-1 trading plan is reported.
Azenta (AZTA) announced full repayment of a $35M vendor loan related to the sale of B Medical Systems. The loan, secured by B Medical Systems' equity, was repaid early with interest. This completes the $63M divestiture, with Azenta receiving the full purchase price in cash. The company's CEO highlighted the completion of the transaction and the retirement of associated credit exposure.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AZTA (Azenta, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent AZTA coverage spans corporate actions, earnings and market movers.
Potential impact on governance and future strategic direction.
The grant is a routine insider compensation award with no cash transaction and modest size.
The cash inflow improves Azenta's balance sheet and frees capital for other investments.
Strong top‑line growth fuels bullish bias.
Leadership change could affect execution of growth plans.
AlphAI scores every news story that mentions AZTA with an AI model for sentiment and relevance, and aggregates insider trades from Azenta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers.
1 min readAzenta (AZTA) granted its interim CEO, Martin D. Madaus, 36,653 restricted stock units (RSUs) on September 14, 2026. The RSUs vest monthly over 12 months and will settle in common stock, increasing Madaus' direct holdings to 44,058 shares. No payment was made for the grant, and no Rule 10b5-1 trading plan is reported.
1 min readAzenta (AZTA) announced full repayment of a $35M vendor loan related to the sale of B Medical Systems. The loan, secured by B Medical Systems' equity, was repaid early with interest. This completes the $63M divestiture, with Azenta receiving the full purchase price in cash. The company's CEO highlighted the completion of the transaction and the retirement of associated credit exposure.
1 min readAzenta (AZTA) reported Q2 revenue of $161.2M, up 12% YoY, beating estimates. Repligen (RGEN) reported $204.1M, up 11.9% YoY, with mixed guidance. Charles River Labs (CRL) reported $1.0B, down 2.7% YoY, but beat estimates. West Pharmaceutical (WST) reported $872.3M, up 13.8% YoY, beating estimates. Stocks reacted accordingly.
3 min readBMF Reports argues SELLAS Life Sciences (SLS) is overvalued due to unclear Phase 3 trial data, predicting 76% downside if it fails. Fugazi Research claims TEN Holdings (XHLD) is a pump-and-dump scheme. A Value Investors’ Club author warns Charter Communications (CHTR) faces debt and competition risks. Notable executive departures include D-Wave Quantum (QBTS), Azenta (AZTA), Amrize (AMRZ), GE Vernova (GEV), and Tesla (TSLA).
2 min readAzenta (AZTA) announced CEO John Marotta's resignation and appointed Dr. Martin Madaus as interim CEO. The company reaffirmed its Q4 2026 revenue guidance of 3-5% growth. Analysts discuss potential impacts on margins and profitability during the leadership transition.
2 min readFunko (FNKO) rose 4.9% after Seaport Research initiated coverage with a Buy rating and $8 target. Hims & Hers Health (HIMS) fell 9.2% due to Visa's Acquirer Monitoring Program enrollment. Azenta (AZTA) dropped 9.1% following CEO John Marotta's resignation. Strategy (MSTR) gained 4.8% after raising $2.01B in equity sales. RUM Group (RUM) increased 6% after a $13.7B AI chip contract.
2 min readAzenta (AZTA) stock fell 10.4% after CEO John Marotta resigned. Interim CEO Dr. Martin Madaus was appointed. Q4 adjusted EBITDA will include a $3M consulting charge. Revenue guidance was reaffirmed. The Nasdaq Composite was down 0.7%.
2 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. AZENTA ANNOUNCES LEADERSHIP TRANSITION Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., August 24, 2026 – Azenta, Inc. (Nasdaq: AZTA) (“Azenta” or “the Company”) to
2 min readAzenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.
7 min read
